HR and breast cancer: To study the clinical, demographic, and socioeconomic differences within Luminal A (HR+/HER2−) and Luminal B (HR+/HER2+) clinical breast cancer subtypes, we gathered 134,639 patients with HR+ and known HER2 receptor status from the SEER database 6.